Q32 Bio Q2 FY26 net loss narrows to $8.95 million - QTTB News | RalliesQ32 Bio Q2 FY26 net loss narrows to $8.95 million
Q
QTTB• Clinical update
- Bempikibart Phase 2a SIGNAL-AA Part B showed 35.3% mean SALT reduction at Week 36; 40% achieved SALT-20 in mITT.
Q2 FY26 financial results
- Q32 Bio posted a net loss of USD 8.95 million, narrowing from USD 9.49 million a year earlier; loss per share improved to USD 0.44.
- R&D expense fell 17.48% to USD 4.26 million, due to lower ADX-097 spend after the program’s November 2025 sale.
- G&A costs rose 21.17% to USD 4.86 million on higher stock-based compensation and other expenses.
- Cash and cash equivalents climbed to USD 106.27 million; July public offering raised about USD 200 million gross.
•
